About Revvity Inc
- Industry: Life Sciences Tools & Services
- Exchange: NEW YORK STOCK EXCHANGE, INC.
- Country: US
- Website: https://www.revvity.com/
Frequently Asked Questions
What is the 52-week range for RVTY?
The 52-week high is $158.28 and the 52-week low is $81.22.
What is the P/E ratio for RVTY?
The Price to Earnings (P/E) ratio is 71.04.
What is the dividend yield for RVTY?
The indicated annual dividend yield is 0.31%.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 3.27%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 8.16%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.52.
Analyst Recommendation Trends
Wall Street analyst consensus for RVTY over the last few months:
Latest RVTY News
Revvity (RVTY) Upgraded to Buy: What Does It Mean for the Stock?
Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Revvity to Hold Earnings Call on November 3, 2026
WALTHAM, Mass., October 02, 2026--Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2026 financial results prior to market open on Tuesday, November 3, 2026. The Company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call.
Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session.
Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Wednesday. Stay informed about the market activity below.
Revvity (RVTY): Buy, Sell, or Hold Post Q2 Earnings?
Revvity has been on fire lately. In the past six months alone, the company’s stock price has rocketed 78%, reaching $150.93 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
RVTY's diagnostics growth, AI-driven demand and life sciences expansion support its outlook, though China and margin pressures pose near-term challenges.
1 Unpopular Stock That Deserves Some Love and 2 Facing Headwinds
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection
Revvity launches a CE-IVDR-certified automated T1D screening kit for children, expanding its GSP platform from newborn screening into early childhood.
Full Transcript: Revvity Q2 2026 Earnings Call
Revvity (NYSE:RVTY) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by Benzinga APIs. For
Sector Update: Healthcare Stocks Advance Late Afternoon
Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index increasing 0.9
Discover which S&P500 stocks are making waves on Thursday.
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Thursday. Discover which stocks are leading as top gainers and losers in today's session.
Here’s How Much You Would Have Made Owning Revvity Stock In The Last 15 Years
Revvity (NYSE:RVTY) has outperformed the market over the past 15 years by 1.11% on an annualized basis producing an average annual return of 14.72%. Currently, Revvity has a market capitalization of $16.82 billion.
Top Midday Stories: Oracle's Data Center Delay; People Withdraws MGM Offer; Revvity's New Diabetes Test
All three major US stock indexes fell in late-morning trading Thursday amid uncertainty in the Middl
Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes
WALTHAM, Mass., September 24, 2026--Revvity, Inc. (NYSE: RVTY) today announced the launch of the GSP® T1D 3plex kit, a fully automated, CE-IVDR-certified, multiplex autoantibody (AAb) detection solution to enable population-wide screening programs that identify children at risk of developing type 1 diabetes (T1D) before symptoms appear.
Revvity Rolls Out GSP T1D 3plex Kit
Revvity, Inc. (NYSE: RVTY) today announced the launch of the GSP® T1D 3plex kit, a fully automated, CE-IVDR-certified, multiplex autoantibody (AAb) detection solution to enable population-wide screening programs that
Is Revvity Stock Outperforming the Dow?
Revvity has notably outperformed the Dow over the past year, and analysts are moderately optimistic about the stock’s prospects.
Why Revvity (RVTY) Is Getting Attention Today
Revvity (RVTY) has drawn fresh attention after recent share price gains, with the stock up about 15% over the past month and roughly 36% over the past 3 months. Over the past year, Revvity has shifted from lagging long term returns, with a 5 year total shareholder return down 16.56%, to strong recent momentum. The 1 year total shareholder return reached 67.67%, and the 90 day share price return came in at 35.67%. Scan beyond Revvity's sharp rebound and explore other hand-picked opportunities...
Capitalize on the Label-Free Detection Market Shift: Track How Danaher, Sartorius, Agilent, Bruker and Revvity Are Disrupting R&D ROI and Reshaping Global Revenue Through 2030
AI-enabled, microfluidic label-free detection is expanding in drug discovery, early diagnostics, food safety and environmental testing, driven by efficient, non-invasive, sustainable workflows.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Label-Free Detection - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Label-Free Detection was valued at US$553 Million in 2024 and is projected to reach US$847 Million by 2030, growing at a CAGR of 7.4
Capitalize on High Content Screening Disruption: Decode How Thermo Fisher Scientific, Danaher, Revvity, and Yokogawa Are Reshaping Global R&D ROI and Revenue
High-content screening is advancing drug discovery and personalized medicine, driven by 3D models, advanced imaging and automated analytics, with opportunities in cancer research and organoids.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "High Content Screening (HCS) - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for High Content Screening (HCS) was valued at US$1.3 Billion in 2024 and is projected to reach US$2.2 Billion by 2030, growing
What Moved Markets This Week
U.S. stocks closed the week mixed as Treasury yields rose amid a Fed rate hike, and fears of AI development grew. Read more about this week's top events on Wall Street.
Fed Raises Rates, Yields Hit 2007 Highs as Fuel Costs Set Records: This Week On Wall Street
The Fed hiked for the first time since 2023; the 10-year yield touched 5.04%, and record diesel prices hit truckers and automakers.
1 Momentum Stock with Promising Prospects and 2 Facing Headwinds
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.
Explore the top gainers and losers within the S&P500 index in today's session.
Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.
Strength Seen in Revvity (RVTY): Can Its 9.1% Jump Turn into More Strength?
Revvity (RVTY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Discover which S&P500 stocks are making waves on Tuesday.
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.
Q2 Rundown: Revvity (NYSE:RVTY) Vs Other Research Tools & Consumables Stocks
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the research tools & consumables industry, including Revvity (NYSE:RVTY) and its peers.
10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today
The 10-year Treasury yield broke 5% for the first time since 2007 as WTI surged past $105 on Saudi pipeline outages, pressuring stocks ahead of the Fed.
Stocks making the biggest moves midday: Skyworks Solutions, Axon, Dave & Buster's, Revvity & more
These are the stocks posting the largest moves midday.
Revvity, Inc. (RVTY) Presents at 2026 Global Healthcare Conference Transcript
Revvity, Inc. (RVTY) 2026 Global Healthcare Conference September 15, 2026 9:05 AM EDTCompany ParticipantsStephen Willoughby - Senior VP of Investor...
VNRX: VolitionRx Prepays Outstanding Balance on the $7,500,000 Lind Senior Secured Convertible Promissory Note Dated May 20, 2025. Review of Papers, Posters, and Videos Released in Mid-2026. Sysmex Collaboration is the 3rd Recent Agreement in the Human Space.
By Steven Ralston, CFA NYSE: VNRX READ THE FULL VNRX RESEARCH REPORT EXECUTIVE OVERVIEW VolitionRx Limited (NYSE: VNRX) continues to advance its multi-pillar epigenetics platform through mid-2026, generating a continued stream of clinical validation across Nu.Q NETs, Nu.Q Cancer, and Capture-Seq. Management has simultaneously decreased operating expenses, which were reduced in the most recent
3 Healthcare Stocks That Fall Short
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 30% gain over the past six months, beating the S&P 500 by 16.7 percentage points.
Revvity to Acquire Human Cell Design to Boost Metabolic Discovery
RVTY's HCD deal is expected to add human pancreatic beta cell models, expanding drug discovery and preclinical research tools for metabolic diseases.
These S&P500 stocks are gapping in today's session
Let's have a look at the S&P500 gap up and gap down stocks in today's session.
Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery
WALTHAM, Mass., September 09, 2026--Revvity, Inc. (NYSE: RVTY) today announced it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases. The acquisition is expected to add HCD’s human pancreatic beta cell models to Revvity’s Life Sciences portfolio, supporting drug discovery, screening and preclinical research, includin
UBS Assumes Revvity at Neutral, Raises Price Target to $140
UBS analyst Doug Schenkel assumes Revvity (NYSE:RVTY) with a Neutral rating and raises Price Target to $140.
Revvity Bets on GLP-1 Boom With Human Cell Design Acquisition
Revvity buys Human Cell Design to expand diabetes and GLP-1 drug discovery tech. Acquisition expected to close in Q4 2026.
Revvity To Acquire French Biotech Firm Human Cell Design To Gain Exposure To Human Cell Models And Preclinical Research Solutions For Diabetes, Obesity And Other Metabolic Diseases
The acquisition is expected to add HCD’s human pancreatic beta cell models to Revvity’s Life Sciences portfolio, supporting drug discovery, screening and preclinical research, including applications in GLP-1 and other
Research Use Recombinant Protein Market Report Now Available — Forecasts Market Growth from $1.11B (2026) to $1.55B by 2031, Profiling Thermo Fisher, Bio-Techne, Merck KGaA, Danaher, Revvity, and Others
500-Page Report Spans 450 Data Tables Across Product, Species, Host Cell, and Application Segments as Human Recombinant Proteins Lead Demand Research Use Recombinant Protein Market Research Use Recombinant Protein Market Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Research Use Recombinant Protein Market by Product, Product Formulation, Species, Host Cell, Application, End User, Region - Global Forecast to 2031" has been added to ResearchAndMarkets.com's offering. Research Use Recombinant Pro
Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?
Revvity's raised 2026 outlook, Diagnostics growth and stronger cash flow brighten the setup, but premium valuation and software risks call for selectivity.
Global Multiplex Assays Market 2026 Edition - Consumables Dominate Multiplex Assays with 68% Market Share
The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with a 34% share, while Asia Pacific is the fastest-growing region at 15.5%; India is forecast to expand at 16.9%. Consumables account for 68% of sales and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, biomarker R&D, molecular diagnostics and laboratory automation. Key players include Thermo Fisher
Keybanc Maintains Overweight on Revvity, Raises Price Target to $165
Keybanc analyst Paul Knight maintains Revvity (NYSE:RVTY) with a Overweight and raises the price target from $125 to $165.
Revvity (RVTY) Stock Looks Fair On Cash Flow Yet Pricey On Earnings
Revvity has delivered a strong 57.5% return over the past year, while valuation checks send mixed signals. The Discounted Cash Flow (DCF) intrinsic value estimate suggests the stock is roughly in line with fair value, and market-based multiples point to a richer price. Revvity’s 57.5% 1 year return sets a high bar for new buyers, who now need the fundamentals to justify a much higher share price base. The key support for the current valuation can come from the company’s ability to convert...
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-21 | Krakowiak Maxwell | -1,631 | $144.53 | $235,728 |
| 2026-09-16 | Vohra Tajinder S | -7,330 | $140.88 | $1,032,650 |
| 2026-08-25 | MICHAS ALEXIS P | -285 | - | - |
| 2026-08-14 | Goldberg Joel S | +27,785 | - | - |
| 2026-08-14 | Goldberg Joel S | -27,785 | - | - |
| 2026-08-13 | Singh Prahlad R. | +59,650 | - | - |
| 2026-08-13 | Singh Prahlad R. | -59,650 | - | - |
| 2026-08-13 | Singh Prahlad R. | +7,636 | - | - |
| 2026-08-13 | Singh Prahlad R. | -7,636 | - | - |
| 2026-07-20 | Gonzales Anita | -85 | $109.48 | $9,306 |
| 2026-05-07 | McMurry-Heath Michelle | +1,265 | - | - |
| 2026-05-07 | McMurry-Heath Michelle | +1,015 | - | - |
| 2026-05-07 | Klobuchar Michael A | +1,265 | - | - |
| 2026-05-07 | Klobuchar Michael A | +1,015 | - | - |
| 2026-05-07 | Witz Pascale | +1,265 | - | - |
| 2026-05-07 | Witz Pascale | +1,015 | - | - |
| 2026-05-07 | Chapin Samuel R. | +1,265 | - | - |
| 2026-05-07 | Chapin Samuel R. | +1,015 | - | - |
| 2026-05-07 | Vounatsos Michel | +1,265 | - | - |
| 2026-05-07 | Vounatsos Michel | +1,015 | - | - |
| 2026-05-07 | Witney Frank | +1,265 | - | - |
| 2026-05-07 | Witney Frank | +1,015 | - | - |
| 2026-05-07 | Vandebroek Sophie V. | +1,265 | - | - |
| 2026-05-07 | Vandebroek Sophie V. | +1,015 | - | - |
| 2026-05-07 | Barrett Peter | +1,265 | - | - |
| 2026-05-07 | Barrett Peter | +1,015 | - | - |
| 2026-05-07 | MICHAS ALEXIS P | +1,467 | - | - |
| 2026-05-07 | MICHAS ALEXIS P | +1,217 | - | - |
| 2026-04-20 | Gonzales Anita | -80 | $92.8 | $7,424 |
| 2026-03-16 | Gonzales Anita | +4,576 | - | - |
| 2026-03-16 | Gonzales Anita | +1,600 | - | - |
| 2026-03-06 | Gonzales Anita | +1,616 | - | - |
| 2026-03-06 | Gonzales Anita | +1,721 | - | - |
| 2026-02-24 | Victor Miriame | +1,862 | - | - |
| 2026-02-24 | Victor Miriame | -1,862 | $97.13 | $180,856 |
| 2026-02-24 | Victor Miriame | +1,862 | $95.74 | $178,268 |
| 2026-02-23 | McMurry-Heath Michelle | -600 | $97.26 | $58,356 |
| 2026-02-17 | Gonzales Anita | -85 | $96.03 | $8,163 |
| 2026-02-17 | Gonzales Anita | -83 | $96.03 | $7,970 |
| 2026-02-17 | Gonzales Anita | -69 | $96.03 | $6,626 |
| 2026-02-17 | Krakowiak Maxwell | -902 | $96.03 | $86,619 |
| 2026-02-17 | Krakowiak Maxwell | -1,457 | $96.03 | $139,916 |
| 2026-02-17 | Victor Miriame | -1,031 | $96.03 | $99,007 |
| 2026-02-17 | Singh Prahlad R. | -6,901 | $96.03 | $662,703 |
| 2026-02-17 | Goldberg Joel S | -1,733 | $96.03 | $166,420 |
| 2026-02-17 | Vohra Tajinder S | -566 | $96.03 | $54,353 |
| 2026-02-05 | Singh Prahlad R. | -25,525 | - | - |
| 2026-02-05 | Singh Prahlad R. | -1,068 | $102.52 | $109,491 |
| 2026-02-05 | Singh Prahlad R. | -3,079 | $101.45 | $312,365 |
| 2026-02-05 | Singh Prahlad R. | -7,885 | $100.63 | $793,468 |
| 2026-02-05 | Singh Prahlad R. | -12,186 | $99.55 | $1,213,116 |
| 2026-02-05 | Singh Prahlad R. | -1,307 | $99.02 | $129,419 |
| 2026-02-05 | Singh Prahlad R. | +25,525 | $92.09 | $2,350,597 |
| 2026-02-05 | Goldberg Joel S | -12,717 | - | - |
| 2026-02-05 | Goldberg Joel S | -532 | $102.52 | $54,541 |
| 2026-02-05 | Goldberg Joel S | -2,217 | $101.33 | $224,649 |
| 2026-02-05 | Goldberg Joel S | -3,544 | $100.5 | $356,172 |
| 2026-02-05 | Goldberg Joel S | -6,424 | $99.47 | $638,995 |
| 2026-02-05 | Goldberg Joel S | +12,717 | $92.09 | $1,171,109 |
| 2026-02-04 | Krakowiak Maxwell | +20,771 | - | - |
| 2026-02-04 | Krakowiak Maxwell | +7,262 | - | - |
| 2026-02-04 | Krakowiak Maxwell | -708 | $101.13 | $71,600 |
| 2026-02-04 | Victor Miriame | +15,449 | - | - |
| 2026-02-04 | Victor Miriame | +5,401 | - | - |
| 2026-02-04 | Victor Miriame | -536 | $101.13 | $54,206 |
| 2026-02-04 | Singh Prahlad R. | +76,647 | - | - |
| 2026-02-04 | Singh Prahlad R. | +26,796 | - | - |
| 2026-02-04 | Singh Prahlad R. | -3,421 | $101.13 | $345,966 |
| 2026-02-04 | Goldberg Joel S | +18,383 | - | - |
| 2026-02-04 | Goldberg Joel S | +6,427 | - | - |
| 2026-02-04 | Goldberg Joel S | -869 | $101.13 | $87,882 |
| 2026-02-04 | Vohra Tajinder S | +12,722 | - | - |
| 2026-02-04 | Vohra Tajinder S | +4,448 | - | - |
| 2026-02-04 | Vohra Tajinder S | -359 | $101.13 | $36,306 |
| 2026-02-02 | Vohra Tajinder S | +5,756 | - | - |
| 2026-02-02 | Vohra Tajinder S | -5,756 | $104.5 | $601,502 |
| 2026-02-02 | Vohra Tajinder S | +5,756 | $92.09 | $530,070 |
| 2025-12-15 | Gonzales Anita | -25 | $100.49 | $2,512 |
| 2025-10-29 | Singh Prahlad R. | +9,420 | - | - |
| 2025-10-29 | Singh Prahlad R. | -9,420 | - | - |